Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial...
Future studies should seek to determine whether patients with BRCA1 mutations and triple-negative breast cancer respond to treatment better than BRCA-negative patients with similar tumor pathology.doi:10.1016/S1043-321X(09)79253-7Comen, E.A....
Kaklamani on Elacestrant for CDK4/6 Inhibitor-Naive ER+ Breast Cancer Treatment T-DXd in ER+/HER2-Low Breast Cancer: Insights From DESTINY-Breast06 Expanding Access to Bispecifics in R/R Multiple Myeloma Treatment Real-World Outcomes of Oral Azacitidine Maintenance in AML Pre...
FDA grants approval to rucaparib for BRCA-positive, advanced ovarian cancer. Rucaparib Now FDA Approved for Pretreated, BRCA Positive Ovarian Cancer The FDA has approved rucaparib (Rubraca) as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 ...
None of the 13 patients had to withdraw from the talazoparib treatment due to side effects, which were limited mainly to fatigue and low blood counts. There were no grade 4 toxicities. Eight of the 13 had triple-negative disease, breast cancer that does not have HER2 or hormonal targets ...
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. Ann Oncol. 2016;27(8):1532–8. 8. Waks AG, Winer EP. Breast Cancer treatment: a review. JAMA. 2019;321(3):288–300. 9. Bardia A, Mayer IA, ...
Here, or onInstagram,Facebook,orYouTube. And learn more about Breast Cancer treatment, prevention, support & more. Join my free FB and Monthly Virtual Emotional Support Group, just for Women Cancer Warriors, Survivors, & Support People, "Growing Through Breast Cancer"...
Much progress has been made in research for prostate cancer in the past decade. There is now greater understanding for the genetic basis of familial prosta... Gerhardt Attard MD a b,Chris Parker FRCR c,Ros A Eeles FRCR d e,... - 《Lancet》 被引量: 21发表: 2016年 Treatment patterns...
I use a feminist standpoint lens to explore the process by which BRCA-positive women came to socially construct and understand their risk for developing breast and/or ovarian cancer and the treatment options they elected post-testing. This study included in-depth interviews with 64 BRCA-positive ...
Background: Metastatic breast cancer in BRCA 2 patients is lacking of target therapy studies. Case: We present a case of a 34-year-old woman affected by a recurrent metastatic breast cancer after 5 years treated with weekly nab-paclitaxel and three weekl